Index for the appropriate vancomycin dosing in premature neonates and infants

Abstract Background In neonates, vancomycin (VCM) is used to treat Gram‐positive bacterial infections. However, VCM blood concentrations are affected by gestational age, bodyweight (BW), and renal function. The initial VCM dose adjustment can therefore be difficult, and few reports have evaluated this issue. In this study, we investigated the factors determining the appropriate VCM dosing schedule in neonates, especially premature infants. Methods The VCM dosage and trough concentrations were retrospectively investigated from the initial treatment to maintenance therapy in neonatal intensive care unit patients who underwent therapeutic drug monitoring. We examined the average single‐administration VCM dosage during maintenance therapy. We then compared the actual VCM dose with that calculated using an index comprising six items that influence the VCM daily dose (postnatal age, gestational age, BW, serum creatinine level, urine output, and lactate level). Results Twenty premature infants were included. The average BW of patients at the initial VCM administration was 975 g. During maintenance therapy, the average VCM dose was 8.4 mg/kg, and the median trough concentration was 12.4 μg/mL. When we applied the six‐item index, 18 of 20 patients (90%) had concordant results between the actual VCM dosing schedule and the VCM calculated using the index. Conclusions The average VCM dose and six‐item index can facilitate the transition from the initial VCM dose to an appropriate dose in many cases and contribute to early treatment in low‐birthweight infants with more variable BW, distribution volumes, and renal function. In conclusion, our six‐item index may help standardize VCM administration in premature infants.

[1]  Takanori Funaki,et al.  Low vancomycin trough concentration in neonates and young infants , 2020, Pediatrics international : official journal of the Japan Pediatric Society.

[2]  D. Levine,et al.  Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Socie , 2020, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[3]  J. Gonçalves,et al.  Vancomycin therapeutic drug monitoring and population pharmacokinetic models in special patient subpopulations , 2018, Pharmacology research & perspectives.

[4]  A. Lodha,et al.  Renal consequences of preterm birth , 2017, Molecular and Cellular Pediatrics.

[5]  K. V. Van Meurs,et al.  Association between Vancomycin Trough Concentration and Area under the Concentration-Time Curve in Neonates , 2014, Antimicrobial Agents and Chemotherapy.

[6]  W. Hoy,et al.  Assessment of renal functional maturation and injury in preterm neonates during the first month of life. , 2014, American journal of physiology. Renal physiology.

[7]  S. Walker,et al.  Determination of Vancomycin Pharmacokinetics in Neonates To Develop Practical Initial Dosing Recommendations , 2014, Antimicrobial Agents and Chemotherapy.

[8]  V. Biran,et al.  Vancomycin continuous infusion in neonates: dosing optimisation and therapeutic drug monitoring , 2012, Archives of Disease in Childhood.

[9]  Jung Hyun Lee Catheter-related bloodstream infections in neonatal intensive care units , 2011, Korean journal of pediatrics.

[10]  Tracie Wilcox Catheter-related bloodstream infections. , 2009, Seminars in interventional radiology.

[11]  J. N. van den Anker,et al.  Vancomycin: pharmacokinetics and administration regimens in neonates. , 2004, Clinical pharmacokinetics.

[12]  J. Connor,et al.  The Influences of Renal Function and Maturation on Vancomycin Elimination in Newborns and Infants , 2001, Journal of clinical pharmacology.

[13]  T. Abraham,et al.  Evaluation of vancomycin target trough attainment with published dosing regimens in the neonatal intensive care unit population. , 2019, Journal of neonatal-perinatal medicine.

[14]  Y. Nishi,et al.  Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring , 2013, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[15]  M. Baum Neonatal nephrology. , 2012, Current opinion in pediatrics.

[16]  H. C. Fernandez,et al.  The correlation between plasma lactate concentrations and early neonatal mortality. , 2012, Revista Brasileira de terapia intensiva.

[17]  M. Rybak,et al.  The pharmacokinetic and pharmacodynamic properties of vancomycin. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.